Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin-family which includes nerve growth factor, neurotrophin-3 and neurotrophin-4/5 [1±4]. BDNF promotes neurite outgrowth and trophic support to certain neurons in the central and peripheral nervous systems. The efficacy of BDNF in the treatment of neurological disorders has been demostrated elsewhere [1, 5±7]. We have previously found that BDNF reduces food intake and lowers blood glucose in obese diabetic models such as C57BL/KsJ-db/db mice [8±10]. This was the first evi- Diabetologia (2001) Abstract Aim/hypothesis. We previously reported that repeated subcutaneous or intracerebroventricular injection of brain-derived neurotrophic factor (BDNF) reduces blood glucose concentrations in obese diabetic C57BL/KsJ-db/db mice. In this study, we assessed the effects of BDNF on insulin action in peripheral tissues of diabetic mice.
dence that a neurotrophin possesses a pleiotrophic effect and functions in the endocrine system as well as in the nervous system.
As an extension of that work we have analysed the hypophagic effect of BDNF on blood glucose in more detail. With a new pellet pair-feeding apparatus, developed by us to regulate feeding precisely between control and BDNF-treated groups, we were able to show that BDNF has a significant hypoglycaemic action in hyperphagic diabetic mice apart from the reduction of food intake [11] . With long-term treatment, the hypoglycaemic action of BDNF was found to be stronger in younger, more hyperinsulinaemic db/db mice than in older, less hyperinsulinaemic db/ db mice [11] . In addition, BDNF enhanced insulindependent hypoglycaemic action in stretozotocin (STZ)-induced Type I diabetic mice [11] . These results suggest that BDNF reduces blood glucose by either enhancing insulin responsiveness or possibly ameliorating insulin resistance in peripheral tissues of diabetic animals.
Insulin resistance in peripheral tissues is a pathological characteristic of patients with Type II (non-insulin-dependent) diabetes mellitus and clinically very important when trying to improve the glucose metabolism of these patients [12, 13] . Insulin resistance is also present in diabetic animal models such as db/db mice, ob/ob mice and Zucker fatty rats [14±16] . Insulin-stimulated activation of insulin receptor tyrosine kinase and phosphatidylinositol (PI) 3-kinase are altered in the peripheral tissues of such diabetic animals [17±19] and this could be at least partly responsible for the reduced insulin action. Thus, the enhancement of insulin responsiveness and the amelioration of insulin resistance are promising profiles for anti diabetic drugs. Thiazolidinediones, a newly-developed class of anti diabetic drugs, have in fact been reported to have such features [20±22] .
Therefore, in order to clarify the action mechanism responsible for BDNF's hypoglycaemic efficacy, it is very important to analyse in detail the effect of BDNF on insulin sensitivity in peripheral tissues. Our objective in this study was to examine whether BDNF modulates the insulin-stimulated activation of insulin receptors and PI 3-kinase in both insulin resistant db/db mice and insulin deficient streptozotocin-induced mice. We also assessed the direct action of BDNF on cultured hepatocytes, adipocytes and muscle cells.
Materials and methods
Animals. Male C57BL/KsJ-db/db mice were obtained from Clea Japan (Tokyo, Japan). Treatment in these mice began at 8 weeks of age. Male C57BL/6Ncrj mice were obtained from Charles River Japan (Tokyo, Japan). These mice were treated with streptozotocin at 6 weeks of age. Male Wistar rats were purchased from Japan SLC (Hamamatsu, Japan). All animals were housed in group cages and maintained in a daily cycle of 12 hours light and 12 hours darkness. Food (CE-2, Clea Japan, Tokyo, Japan) and water were given freely except to mice in the fasting experiments. All animal experiments were conducted according to the guidelines of the Sumitomo Pharmaceuticals Committee on Animal Research.
Materials. Human recombinant BDNF (n-terminal methionine-free) was from Regeneron Pharmaceuticals (Tarrytown, N. Y., USA). PBS containing 0.01 % Tween 80 and 1 % mannitol was used as a vehicle for subcutaneous injection of BDNF. Artificial cerebrospinal fluid (aCSF; 0.166 g/l CaCl 2 , 7.014 g/l NaCl, 0.298 g/l KCl, 0.203 g/l MgCl 2 /6H 2 O and 2.10 g/l NaH-CO 3 ) was used as a vehicle for intracerebroventricular injection. Human regular insulin (Novolin R) was from Novo Nordisk (Copenhagen, Denmark). Metformin (dimethylbiguanide) was from Sigma (St. Louis, Mo., USA). a-Minimal essential medium (a-MEM), Dulbecco's modified Eagle's medium (DMEM) and fetal calf serum (FCS) were from Gibco BRL (Grand Island, N. Y. USA). 2-deoxy [1,2- 3 H]glucose, [g-
32
P]ATP and ACSII were from Amersham Life Science (Buckinghamshire, England). Protein G sepharose beads were from Amersham Pharmacia Biotech (Uppsala, Sweden). Monoclonal anti-phosphotyrosine antibody (4G10), polyclonal anti-IRS-1 antibody and polyclonal anti-IRS-2 antibody were from Upstate Biotechnology (Lake Placid, N. Y. USA) and monoclonal anti-phosphotyrosine antibody (PY20), monoclonal anti-insulin receptor b subunit antibody (29B4) and polyclonal anti-insulin receptor b subunit antibody (C-19) were from Santa Cruz Biotechnology (Santa Cruz, Calif., USA).
Cell culture. Rat L6 muscle cells were kindly given by Dr A. Klip (the Hospital for Sick Children, Toronto, Canada). The cells were seeded on 24-well plates (5 10 4 cells/well) or on a 100 mm dish (1 10 6 cells/dish) and cultured in a-MEM containing 10 % FCS under a humidified atmosphere (5 % CO 2 ). Confluent cells were then cultured for 2 days in a-MEM containing 2 % FCS and used in the experiment.
Mouse 3T3-L1 adipocytes were purchased from ATCC (Rockville, Md., USA). The cells were seeded on 24-well gelatin-coated plates (2 10 4 cells/well) or on a 100 mm gelatincoated dish (1 10 6 cells/dish) and cultured in DMEM containing 10 % FCS under a humidified atmosphere containing (5 % CO 2 ). Confluent cells were then cultured for 2 days in DMEM containing 0.5 mmol/l isobutylmethylxantine, 2.5 mmol/l dexamethazone, 8 mg/ml biotin, 10 mg/ml insulin and 10 % FCS. The media was changed 2 days later to DMEM containing 8 mg/ml biotin and 10 % FCS and replaced every other day thereafter. The cells were then used in the experiment 8 to 11 days after confluence.
A primary culture of rat hepatocytes was isolated from male Wistar rats by collagenase perfusion methods [23] . The cells were seeded on 24-well plates (3 10 5 cells/well) or on a 100 mm dish (6 10 6 cells/dish) and cultured for 16 h in Williams medium E containing 10 nmol/l dexamethazone and 5 % FCS under a humidified atmosphere (5 % CO 2 ).
Insulin signal transduction in cultured cells. The above cells cultured in 100 mm dishes were serum starved for 24 h and pre-incubated with BDNF (100 ng/ml) for 2 and 24 h before insulin stimulation. The cells were then incubated with insulin (100 nmol/l) or saline for 10 min at 37 C. They were washed 2 times with ice-cold PBS and immediately frozen in liquid nitrogen.
2-deoxyglucose uptake in vitro. The L6 muscle cells and 3T3-L1 adipocytes cultured in 24-well plates were pre-incubated with BDNF (0, 10, 100 and 1000 ng/ml) for 24 h before the glucose uptake experiment. They were then washed 3 times and incubated in Krebs-Ringer-phosphate buffer (pH 7.4) for 30 min at 37 C. The cells were next incubated with insulin (100 nmol/l) or saline for 15 min. The glucose uptake experiment was started by adding 2-deoxy [1,2- 3 H]glucose (0.5 mCi/ well) and unlabelled 2-deoxyglucose (0.1 mmol/l final concentration). Glucose uptake was terminated by removing the reaction medium and washing the cells 3 times with ice-cold PBS containing 0.1 mmol/l phloretin. Cells were suspended with trypsin/EDTA and counted in a liquid scintillator (ACS II).
Effect of BDNF on glucose production in vitro. Isolated hepatocytes cultured in 24-well plates were then washed twice with PBS and incubated with BDNF (0, 1, 10 and 100 ng/ml) or metformin (10 mmol/l) in glucose free Hank's solution containing 0.1 % fructose, 100 nmol/l glucagon for 6 h at 37 C. Newly produced glucose in the medium was measured by the Glucose C II-Test Wako (Mutarotase-glucose oxidase method, Wako Chemical, Osaka, Japan).
Effect of repeated BDNF injection on tyrosine phosphorylation of insulin receptors in db/db mice. We gave BDNF (20 mg/kg/ day) or vehicle subcutaneously to db/db mice for 14 days. On day 14, tyrosine phosphorylation of insulin receptors and phosphatidylinositol (PI) 3-kinase activity in liver, hindlimb skeletal muscle, interscapular brown adipose tissue and epididymal adipose tissue were analysed with insulin stimulation [138 units/ kg (about 5 units/mouse); intravenous injection into tail vein] after 16 h fasting. Saline instead of insulin was injected to the negative control group without insulin stimulation. Four groups of db/db mice were analysed: (1) vehicle control group without insulin stimulation; (2) vehicle control group with insulin stimulation; (3) BDNF-treated group without insulin stimulation; (4) BDNF-treated group with insulin stimulation. Mice that received insulin or saline were decapitated 3 min after the injection. The liver, hindlimb skeletal muscle, interscapular brown adipose tissue and epididymal adipose tissue were then immediately excised and frozen in liquid nitrogen.
Effect of a single BDNF injection on insulin signal transduction in streptozotocin-induced diabetic mice. Diabetes was induced in C57BL/6Ncrj mice by two consecutive daily intraperitoneal injections of streptozotocin (STZ, 200 mg/kg) dissolved in citrate buffer (pH 5.5). On the third day after the last STZ injection, insulin signalling was analysed after a single subcutaneous injection of BDNF or vehicle in STZ-induced diabetic mice (STZ-mice). Mice were fasted after BDNF or vehicle treatment. To assess the effect of a single injection of BDNF on insulin signal transduction under basal conditions, mice were decapitated without insulin stimulation 2 h after a single BDNF (70 mg/kg, s. c.) or vehicle treatment. The liver and hindlimb skeletal muscle were then immediately excised and frozen in liquid nitrogen. Next, the effect of BDNF was investigated on insulin signalling under insulin-stimulated conditions. Two hours after a single BDNF (70 mg/kg, s. c.) or vehicle treatment, with human regular insulin (1 unit/kg) was injected into the tail vein of STZ-mice. These mice were then decapitated 3 min and 10 min after insulin injection. Similarly, the liver and hindlimb skeletal muscle were then immediately excised and frozen in liquid nitrogen.
In the case of intracerebroventricular BDNF injection, STZ-mice were anaesthetized with diethyl ether, the bregma was identified and 5 mg BDNF/mouse (3 ml/shot) or aCSF was injected into the lateral ventricle. Experimental protocols except for injection of BDNF were the same as those described above.
Immunoprecipitation and western blotting. Frozen tissues or cells were homogenized in ice-cold lysis buffer (20 mmol/ TRIS-HCl (pH 7.4), 0.15 mol/l NaCl, 1 % NP-40, 0.1 % sodium deoxycholate, 5 mmol/l EDTA, 10 mmol/l sodium fluoride, 2 mmol/l sodium orthovanadate, 1 mmol/l phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin and 10 mg/ml leupepsin). Homogenates were centrifuged and equal protein amounts of supernatants were immunoprecipitated with anti-insulin receptor b-subunit antibody (29B4) and protein G-sepharose. The immunoprecipitates were studied with SDS-PAGE and western blot analysis using anti-phosphotyrosine antibody (4G10) or anti-insulin receptor b-subunit antibody (C-19). The blots were quantified by densitometry.
Phosphatidylinositol (P1) 3-kinase activity. Frozen tissues or cells were homogenised in ice-cold lysis buffer [20 mmol/l TRIS-HCl (pH 8.0), 0.137 mol/l NaCl, 1 mmol/l MgCl2, 1 mmol/l CaCl 2 , 10 % glycerol, 1 % NP-40, 1 mmol/l sodium orthovanadate, 1 mmol/l PMSF and 1 mmol/l dithiothreitol (DTT)]. Homogenates were centrifuged, and equal protein amounts of supernatants were immunoprecipitated with antiphosphotyrosine antibody (PY20), anti-IRS-1 antibody, or anti-IRS-2 antibody and then protein G-sepharose. Immunoprecipitates were washed twice with PBS containing 1 % NP-40, twice with 0.1 mol/l TRIS-HCl (pH 7.4) containing 0.5 mmol/l LiCl and twice with 10 mmol/l TRIS-HCl (pH 7.4) containing 0.1 mol/l NaCl. The pellets were suspended in 50 mmol/l hydroxyethylpiperazin-ethanesulphonic acid HE-PES) (pH 7.1) containing 0.2 mg/ml PI, 1 mmol/l EGTA and 1 mmol/l sodium phosphate. The reaction was then started by adding 5 mCi [g-32 P]ATP, and 250 mmol/l ATP and 50 mmol/l MgCl 2 . After 6 min at room temperature 1 N HCl and chloroform:methanol (1:1) were added to terminate the reaction. The samples were centrifuged and the lower organic phase was removed and applied to a silica gel thin layer chromatography plate coated with 1 % potassium oxalate and 2 mmol/l EDTA. The plate was developed in chloroform:methanol:5 N ammonia (9:7:2), dried and visualised using a BAS2000 bio-imaging analyser (Fuji Photo Film, Tokyo, Japan).
Blood glucose. Blood samples were collected from tail vein and blood glucose was measured by the Glucose CII-Test Wako (Wako Chemical, Osaka, Japan).
Statistical analysis. All data are presented as means SD. Differences between individual groups were analysed by Student's t-test. Statistical calculations were carried out using SAS software (SAS Institute, Cary, N. C., USA). A p value of less than 0.05 was considered statistically significant.
Results
Long-term effect of BDNF injection on tyrosine phosphorylation of insulin receptors. We have previously shown that the repeated injection of BDNF reduces blood glucose concentration in db/db mice [8±11]. Furthermore, the hypoglycaemic effect of BDNF was found to be stronger in younger, more hyperinsulinaemic db/db mice than in older, less hyperinsulinaemic animals [8] . This suggests that BDNF produces its hypoglycaemic effect in db/db mice by enhancing insulin responsiveness or alleviating insulin resistance or both. To examine whether there is an actual im-provement in insulin responsiveness we next analysed insulin signal transduction in the peripheral tissues of db/db mice that received repeated subcutaneous injection of BDNF (20 mg/kg) for 14 days. The injection of BDNF for 14 days significantly reduced blood glucose concentrations in db/db mice ( Table 1) . On day 14, three minutes after intravenous treatment with insulin or saline, the liver, hindlimb skeletal muscle, interscapular brown adipose tissue and epididymal adipose tissue were excised and subjected to western blot analysis. The tissue extracts were immunoprecipitated with anti-insulin receptor b subunit (IRb) antibody and the blots were detected with anti-phosphotyrosine antibody after electrophoresis ( Fig. 1 A, C, E, G). Without insulin injection, only faint tyrosine-phosphorylated bands were observed in each tissue from db/db mice given vehicle or BDNF and there was no significant difference in phosphorylation between vehicle-treated mice and BDNF-treated mice ( Fig. 1 B, D, F, H) . Next, 3 min after intravenous injection with insulin (138 U/kg), tyrosine phosphorylation of insulin receptors was clearly detected in each tissue from db/db mice who had been given vehicle. After repeated injection of BDNF, insulin-stimulated tyrosine phosphorylation of insulin receptors in the livers of db/db mice were significantly increased by 2.6-fold compared with those of vehicle-treated mice (Fig. 1 B) . Furthermore, there was no statistically significant difference but a tendency to increase insulin-stimulated tyrosine phosphorylation in skeletal muscles and interscapular brown adipose tissue from db/db mice given BDNF when compared with those of vehicle-treated mice (1.2-fold in each tissue) (Fig. 1 D, F) . In contrast, no change was observed in insulin-stimulated tyrosine phosphorylation of epididymal adipose tissue in vehicle-treated or BDNF-treated mice (Fig. 1 H) . We also measured the IRb content in each tissue by western blotting with anti-IRb antibody using the same immunoprecipitates. There was no significant difference in tissue IRb content between the db/db mice given vehicle and those given BDNF (Fig. 1 A, C, E, G) .
Long-term effect of BDNF injection on phosphatidylinositol 3-kinase activity in db/db mice. To study the effect of BDNF on insulin-triggered signalling, phosphatidylinositol (PI) 3-kinase activity was also analysed in the peripheral tissues (liver, hindlimb skeletal muscle, interscapular brown adipose tissue and epididymal adipose tissue) after repeated subcutaneous injection of BDNF (20 mg/kg) for 14 days. Extracts of these tissues were immunoprecipitated with anti-phosphotyrosine antibody and PI 3-kinase activity in each immunoprecipitate was measured (Fig. 2 A, C, E, G) . Without insulin injection, no significant difference in PI 3-kinase activity was observed between tissues of db/db mice given vehicle and those given BDNF (Fig. 2 B, D, F, H) . On the other hand, insulin-stimulated PI 3-kinase activity in liver, skeletal muscle and interscapular brown adipose tissue of db/db mice given BDNF was significantly increased by 1.6-fold, 1.8-fold and 1.9-fold, respectively, compared with db/db mice given vehicle (Fig. 2 B, D, F) . These findings indicate that repeated injection of BDNF enhances insulin responsiveness in periphereal tissues of db/db mice. No significant difference in insulin-stimulated PI 3-kinase activity in epididymal adipose tissue was observed between mice given vehicle and those given BDNF (Fig. 2H ).
Rapid effect of subcutaneous BDNF injection on tyrosine phosphorylation of insulin receptors in streptozotocin-treated mice. The fact that BDNF showed a hypoglycaemic effect in several diabetic animals raises another possibility, namely that long-term treatment of BDNF alleviates glucose toxicity and enhances insulin responsiveness. We therefore decided to study the rapid effect of BDNF on insulin responsiveness in peripheral tissues in vivo.
Previously we have shown that BDNF in combination with insulin rapidly enhances the hypoglycaemic effect of insulin in streptozotocin (STZ)-induced diabetic mice [11] . No such effect was observed with a single BDNF injection [11] . In this study, we examined the rapid effect of BDNF on tyrosine phosphorylation of insulin receptors using this STZ-mice model. Two hours after subcutaneous injection of BDNF or vehicle, insulin was intravenously injected into STZ-mice. Insulin receptor tyrosine residues were phosphorylated by insulin treatment in both liver and skeletal muscle from STZ-mice given vehicle (Fig. 3) . Compared with these mice, tyrosine phosphorylation of insulin receptors was significantly enhanced in livers from STZ-mice given BDNF at 3 and 10 min after insulin stimulation (1.7-fold and 3.8-fold, respectively). In contrast, BDNF showed no effect on tyrosine phosphorylation of insulin receptors in skeletal muscle. There was no significant difference in the IRb content of liver and skeletal muscle between STZmice given vehicle and those given BDNF (Fig. 3  A, C) . Rapid effect of subcutaneous BDNF injection on phosphatidylinositol 3-kinase activity in streptozotocin-induced diabetic mice. PI 3-kinase activity was also analysed in peripheral tissues from STZ-mice 2 h after a single subcutaneous injection of BDNF or vehicle. Ten minutes after insulin injection, PI 3-kinase activity was significantly increased by 1.8-fold in livers from STZ-mice given BDNF compared with those given vehicle (Fig. 4A, B) . Three minutes after insulin injection a 1.5-fold increase of PI 3-kinase activity was observed in livers from STZ-mice given BDNF compared with those given vehicle (Fig. 4 A,  B) . Insulin treatment increased PI 3-kinase activity in skeletal muscle, but there was no further enhancement with BDNF (Fig. 4 C, D) .
Direct effect of BDNF on insulin signalling in cultured hepatocytes, L6 muscle cells and 3T3-L1 adipocytes.
To clarify the action mechanism of BDNF on peripheral tissues, we studied the direct effect of BDNF on . The cells preincubated with BDNF (100 ng/ml) for 2 or 24 h were stimulated with insulin (100 nmol/l) or saline for 10 min followed by measurement of tyrosine phosphorylation of insulin receptor and PI 3-kinase activity. With insulin stimulation there was an increase in both tyrosine phosphorylation of insulin receptor and PI 3-kinase activity in each cell. BDNF did not affect either tyrosine phosporylation of insulin receptor or PI 3-kinase activity in insulin-treated cultured cells (Fig. 5) . The basal activity of these parameters was not altered with BDNF treatment (Fig. 5) .
Direct effect of BDNF on glucose uptake in L6 muscle cells and 3T3-L1 adiopocytes and glucose output in cultured hepatocytes. In addition to actions on the insulin signalling pathway, we examined the direct effect of BDNF on insulin-stimulated 2-deoxy glucose (2-DG) uptake into cultured cells (L6 muscle cells and differentiated 3T3-L1 adipocytes). Insulin increased 2-DG uptake into L6 muscle cells and differentiated 3T3-L1 cells (Table 2) . No effect of BDNF was observed on insulin-stimulated 2-DG uptake (Table 2) . We also studied the direct effect of BDNF on glucose metabolism in a primary culture of rat hepatocytes. Glucose concentration in cultured medium of the primary hepatocytes increased, possibly due to gluconeogenesis. After incubation with 10 mmol/l metformin for 6 h, the glucose concentration in the medium was lower than the untreated control (Table 3 ). This indicates that In contrast, incubation with 1±100 ng/ml BDNF for 6 h did not affect the glucose concentration of the cultured medium (Table 3) .
Rapid effect of intracerebroventricular BDNF injection on insulin signal transduction in streptozotocininduced dabetic mice. Because BDNF showed no obvious effects on insulin action in cultured hepatocytes, myotubles and adipocytes, we examined whether or not the central BDNF injection rapidly affects insulin signalling in vivo. Two hours after intracerebroventricular injection of BDNF or aCSF, insulin was intravenously injected into STZ-mice and then tyrosine phosphorylation of insulin receptor and PI 3-kinase activity in liver and skeletal muscle of the mice were measured. We found that BDNF given intracerebroventricularly enhanced insulinstimulated tyrosine phosporylation of insulin receptor and phosphotyrosine-associated PI 3-kinase activity in liver compared with aCSF injection (Fig. 6 A,  C) . In contrast, BDNF showed no effect on insulinstimulated tyrosine phosphorylation of insulin receptor and PI 3-kinase activity in skeletal muscle (Fig. 6  B, D) . Moreover, to assess the effect of BDNF on insulin signalling in details, we examined the IRS-1 or IRS-2 associated PI 3-kinase activity in liver. BDNF enhanced insulin-stimulated IRS-2 associated PI 3-kinase activity compared with aCSF (Fig. 6 F) , although BDNF had no effect on insulin-stimulated IRS-1 associated PI 3-kinase activity (Fig. 6 E) .
Discussion
Previously we have shown that repeated subcutaneous injection of BDNF reduced blood glucose concentrations in obese and hyperinsulinaemic db/db mice [8±11]. Because db/db mice show decreased insulin responsiveness in peripheral tissues [24] , it is possible that enhancement of insulin responsiveness in peripheral tissues reduces blood glucose concentration of db/db mice. In this study, we have thus investigated whether BDNF treatment modulates insulin-induced activation of the insulin receptor and its downstream signalling elements in db/db mice. Repeated injection of BDNF enhanced insulin-triggered tyrosine phosphorylation of the insulin receptor in Moreover, repeated injection of BDNF enhanced insulin-stimulated PI 3-kinase activity, which mediates a variety of metabolic actions of insulin [25, 26] in the liver, skeletal muscle and interscapular brown adipose tissue, suggesting that BDNF ameliorates insulin responsiveness in peripheral tissues. It should, however, be noted that these events could be a secondary effect of reducing glucose toxicity or food intake during the long-term treatment of the hypoglycaemic, anorexic agent. Therefore, it is important to evaluate the possible direct or rapid action of BDNF on peripheral tissues.
To elucidate whether BDNF exerts a rapid effect on insulin responsiveness, we used a STZ-induced diabetic model. We have previously shown that concomitant injection of BDNF with insulin enhances the hypoglycaemic action of insulin in STZ-mice [11] . We have now shown that BDNF enhanced insulin-induced tyrosine phosphorylation of the insulin receptor in the liver of STZ mice whereas the protein content of the receptor was not altered. Because the effect of BDNF was evident within 2 h and food was removed after BDNF injection, it is not likely that this effect occurred through anorexic action of BDNF or reducing glucose toxicity. While repeated injection of BDNF enhanced insulin signalling in skeletal muscle in db/db mice, no significant rapid effect was observed in skeletal muscle of STZ-mice, suggesting that the effect of BDNF on skeletal muscle of db/db mice might be due to ameliorated glucose toxicity caused by long-term treatment. At this point, we do not know the mechanism how BDNF enhances the tyrosine phosphorylation of the insulin receptor. It has been reported that protein tyrosine phosphatases are involved in the regulation of insulin signalling pathways [27] or that serine phosphorylation of the receptor affects its kinase activity [28] . Therefore, theoretically, BDNF is capable of affecting the insulin receptor kinase through modulating one of these phenomena. Further studies are required to elucidate the mechanism of BDNF on the enhancement of the insulin receptor activity.
Treatment of BDNF resulted in a significant increase in insulin-induced PI 3-kinase activity coprecipitated with IRS-2 with no significant change in that coprecipitated with IRS-1. These results might be explained if IRS-2 possesses stronger affinity to the insulin receptor than IRS-1. The difference in the affinities of IRS proteins to the receptor has not been well characterised. Yeast-two hybrid experiments showed, however, that IRS-1 interacts with the insulin receptor only through the PTB domain whereas IRS-2 interacts with the receptor through the PTB and KRLB domains [29, 30] . It is thus possible that the affinity of each IRS protein to the insulin receptor could be different. We do not, however, exclude the possibility that BDNF affects an unidentified pathway that selectively enhances the signal to IRS-2.
BDNF is a neurotrophic factor and its receptor, trk B, is predominantly expressed in the central nervous system [31] . In our preliminary experiments, however, a truncated form of BDNF receptor trk B and its association protein, p75, were found expressed in the cultured cells used in this study (data not shown). We thus assessed the effect of BDNF on the insulin receptor signalling along with glucose metabolism of cultured cells. We did not, however, find any effect of BDNF on the insulin receptor kinase or PI 3-kinase activity induced by insulin. Moreover, incubation with the cells with BDNF had no effects on glucose uptake into cultured muscle cells or adipocytes, or on glucose production in cultured hepatocytes. Although it has been reported that BDNF stimulates tyrosine phosphorylation of IRS-1 and IRS-2 as well as their association with PI 3-kinase in cultured cerebral cortical neurons [32] , BDNF does not seem to affect the insulin signalling or to exert insulin-mimicked actions in these cultured cells.
We have previously shown that intracerebroventricular injection of BDNF in db/db mice reduced both blood glucose and food intake at a dose as low as approximately 1/100 of the effective dose with subcutaneous injection [11] . In this study, we have shown that an intracerebroventricular injection of BDNF enhanced insulin responsiveness in the liver of STZmice. These results suggest that the effects of BDNF on reducing glucose concentration and enhancing the insulin signalling occurred through its actions in the central nervous system. This profile of BDNF action reminds us of the anorectic protein, leptin, which rapidly stimulates glucose uptake and glucose turnover in normoglycaemic C57BL mice and hyperglycaemic ob/ob mice following intracerebroventricular infusion [33, 34] . Intrahypothalamic injection of leptin acutely enhances glucose uptake in peripheral tissues of normal rats, an effect which is enhanced synergistically with insulin [35, 36] . In addition, some reports have shown that long-term treatment of leptin also enhances insulin sensitivity [37, 38] .
Although leptin drastically reduces body weight in leptin-deficient ob/ob mice and normal rodents it had not been clear whether leptin has hypoglycaemic action against altered glucose metabolism. But recently it has been reported that the hypoglycaemic action of insulin increased in transgenic mice overexpressing Primary cultured rat hepatocytes were incubated with BDNF or metformin (10 mmol/l) in glucose free Hank's solution containing 0.1 % fructose and 100 nmol/l glucagon for 6 h. Glucose concentration in the medium was measured. Data are shown as means SD (n = 3) Cells were preincubated with BDNF for 24 h. Subsequently 2-deoxy[1,2-3 H]glucose uptake was measured under basal or insulinstimulated (100 nmol/l) conditions. Data are shown as means SD in units of pmol/min per well (n = 3) leptin in liver compared with non-transgenic littermates [39] . In liver and skeletal muscle from these transgenic mice, insulin-triggered tyrosine phosphorylation of insulin receptors and PI 3-kinase activity was enhanced [39] . This profile of leptin is similar to our findings on the action of BDNF. Both leptin and BDNF might share the same mechanism in regulating insulin responsiveness and glucose metabolism.
In summary, we have shown here that BDNF enhances the insulin receptor signalling in the liver of STZ-induced diabetic mice and that this effect of BDNF probably occurred through its action in the central nervous system. At this point, it is not clear if the modulation of the insulin signalling in the liver is related to the enhancement of hypoglycaemic action of insulin by BDNF. Recent findings, however, on the liver-specific insulin receptor knockout mice [40] or on IRS-2 knockout mice [41] imply that the insulin signalling or the IRS-2 mediated signalling in the liver is importart to regulate glucose homeostasis. Very recently, it has been reported that mice, being heterozygous for targeted disruption of the BDNF gene, exhibit hyperphagia and obesity [42, 43] . Moreover, these mice show hyperleptinemia and hyperinsulinaemia [43] . These interesting results further support the physiological significance of BDNF in weight control and glucose metabolism. Further detailed studies will be needed to show the molecular mechanism of BDNF in regulating glucose metabolism.
